A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

We determined the RP2D for the combination of orally administered FdCyd and THU and measured prolonged stable disease and tumor suppressor gene hypomethylation in some patients, suggesting potential clinical benefit and molecular activity for this regimen in some patients. The paucity of tumor DNMT1 decreases and p16 re-expression are consistent with the lack of clinical response. However, it may also reflect the timing of on-treatment biopsies (following the 1-week break in FdCyd administration), since increases in p16-expressing CTCs were measured for the majority of CTC-assessable patients.

Authors

Institutions

Publication Details

Journal
Cancer Chemotherapy and Pharmacology
Published
2025-12-22
DOI
https://doi.org/10.1007/s00280-025-04844-y
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Shivaani Kummar, Jennifer Zlott, Mariam M. Konaté, Vincent Chung et al.
Cancer Chemotherapy and Pharmacology
Epigenetics and DNA Methylation
article

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Shivaani Kummar, Jennifer Zlott, Mariam M. Konaté, Vincent Chung, Jan H. Beumer, Larry Rubinstein, Joseph M. Covey, J. Doroshow, Richard Piekarz, Ralph E. Parchment, Lihua H. Wang, Lamin Juwara, Karen Kelly, Edward M. Newman, Julianne L. Holleran, Robert J. Kinders, Sarah B. Miller, Heinz-Josef Lenz, Alice P. Chen, Geraldine O’Sullivan Coyne, Katherine V. Ferry-Galow, Liza C. Villaruz
article en

Abstract

We determined the RP2D for the combination of orally administered FdCyd and THU and measured prolonged stable disease and tumor suppressor gene hypomethylation in some patients, suggesting potential clinical benefit and molecular activity for this regimen in some patients. The paucity of tumor DNMT1 decreases and p16 re-expression are consistent with the lack of clinical response. However, it may also reflect the timing of on-treatment biopsies (following the 1-week break in FdCyd administration), since increases in p16-expressing CTCs were measured for the majority of CTC-assessable patients.

Cancer Chemotherapy and PharmacologyVol. 96(1)
University of Southern California (US), City Of Hope National Medical Center (US), Johns Hopkins University (US), Oregon Health & Science University (US), University of Pittsburgh (US), International Association for the Study of Lung Cancer (US), UPMC Hillman Cancer Center (US), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (MY), University of Pittsburgh Medical Center (US), National Cancer Institute (US), University of California, Davis (US)
National Institutes of Health
Good health and well-being
Openalex Percentile: Top 37%
Epigenetics and DNA Methylation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.